Table 1 Baseline characteristics by treatment group a
Characteristic | Olanzapine-LAI (n= 598) | Sub-therapeutic olanzapine-LAI (n= 144) | Oral olanzapine (n= 322) |
|---|---|---|---|
Male (%) | 65.2 | 66.7 | 64.9 |
Working for pay (%) | 20.5 | 18.1 | 14.1 |
Living independently (%) | 21.2 | 17.4 | 18.8 |
At least one functional activity (%) | 83.6 | 77.1 | 83.8 |
Any suicide threat (%) | 3.4 | 5.6 | 1.9 |
Prior psychiatric hospitalization (%) | 4.68 | 6.94 | 4.97 |
Current tobacco use (%) | 48.1 | 49.3 | 49.8 |
Geographical region (%) | Â | Â | Â |
   America | 29.8 | 31.3 | 31.4 |
   Eastern Europe | 30.1 | 29.2 | 29.2 |
   Western Europe | 29.8 | 27.8 | 30.1 |
   Other | 10.4 | 11.8 | 9.3 |
Age in years, mean (SD) | 38.8 (11.1) | 39.5 (11.6) | 39.0 (11.6) |
Age at onset, years, mean (SD) | 25.6 (8.0) | 26.1 (9.2) | 25.6 (8.4) |
Body mass index (BMI), kg/m 2 , mean (SD) | 26.5 (5.1) | 26.8 (5.2) | 26.4 (5.1) |
PANSS total, mean (SD) | 55.4 (15.5) | 57.8 (15.9) | 56.1 (15.6) |
CGI-S score, mean (SD) | 3.1 (0.9) | 3.2 (0.9) | 3.1 (1.0) |
DAI score, mean (SD) | 7.4 (1.8) | 7.3 (1.9) | 7.5 (1.7) |
SF-36 physical score, mean (SD) | 49.4 (8.2) | 48.5 (8.7) | 49.7 (8.1) |
SF-36 mental score, mean (SD) | 42.7 (11.1) | 42.9 (11.8) | 43.1 (11.9) |
Psychiatric outpatient visits before baseline, mean (SD) | 10.2 (10.1) | 9.5 (10.2) | 9.7 (10.4) |